Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.

被引：17

作者：

Fernando, Hiran C.

Yang, Jing

Ferraro, Geri L.

Keller, Steven M.

机构：

[1] INOVA Fairfax Med Campus, Dept Surg, Falls Church, VA USA

[2] INOVA Fairfax Med Campus, Dept Thorac Surg, Falls Church, VA USA

[3] Merck & Co Inc, Kenilworth, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.TPS8583

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS8583

引用

页数：2

共 50 条

[41] Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1%
Lopes, G.
Wu, Y.
Kudaba, I.
Kowalski, D.
Cho, B.
Turna, H.
De Castro, G., Jr.
Srimuninnimit, V.
Laktionov, K.
Bondarenko, I.
Kubota, K.
Lubiniecki, G.
Zhang, J.
Kush, D.
Mok, T.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S152 - S152
[42] A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy.
Ciardiello, Fortunato
Bang, Yung-Jue
Bendell, Johanna C.
Cervantes, Andres
Brachmann, Rainer Karl
Zhang, Yuting
Raponi, Mitch
Farin, Heinrich
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[43] KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma
Tabernero, J.
Bang, Y.
Van Cutsem, E.
Fuchs, C.
Janjigian, Y.
Bhagia, P.
Li, K.
Adelberg, D.
Qin, S.
ANNALS OF ONCOLOGY, 2020, 31 : S101 - S102
[44] KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
Ferrucci, Pier Francesco
Di Giacomo, Anna Maria
Del Vecchio, Michele
Atkinson, Victoria
Schmidt, Henrik
Schachter, Jacob
Queirolo, Paola
Long, Georgina, V
Stephens, Rosalie
Svane, Inge Marie
Lotem, Michal
Abu-Amna, Mahmoud
Gasal, Eduard
Ghori, Razi
Diede, Scott J.
Croydon, Elizabeth S.
Ribas, Antoni
Ascierto, Paolo Antonio
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[45] MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer-A randomized, double-blind, placebo-controlled, phase 3 study.
Janjigian, Yelena Y.
Van Cutsem, Eric
Muro, Kei
Wainberg, Zev A.
Al-Batran, Salah-Eddin
Hyung, Woo Jin
Molena, Daniela
Evans, Brent
Ruscica, Dario
Robbins, Scott H.
Negro, Alejandra
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[46] Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre double-blind, randomised, phase 3 trial
Long, Georgina, V
Luke, Jason J.
Khattak, Muhammad A.
Merino, Luis de la Cruz
Del Vecchio, Michele
Rutkowski, Piotr
Spagnolo, Francesco
Mackiewicz, Jacek
Chiarion-Sileni, Vanna
Kirkwood, John M.
Robert, Caroline
Grob, Jean-Jacques
de Galitiis, Federica
Schadendorf, Dirk
Carlino, Matteo S.
Mohr, Peter
Dummer, Reinhard
Gershenwald, Jeffrey E.
Yoon, Charles H.
Wu, Xi Lawrence
Fukunaga-Kalabis, Mizuho
Krepler, Clemens
Eggermont, Alexander M. M.
Ascierto, Paolo A.
LANCET ONCOLOGY, 2022, 23 (11): : 1378 - 1388
[47] A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 2 STUDY OF GANITUMAB OR RILOTUMUMAB WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (SCLC)
Glisson, Bonnie
Kazarnowicz, Andrzej
Nackaerts, Kristiaan
Orlov, Sergey
Ramlau, Rodryg
Besse, Benjamin
Cobo Dols, Manuel
Menon, Hari
Paz-Ares Rodriguez, Luis
Zhang, Yilong
Zhu, Min
Jiang, Yizhou
Loh, Elwyn
Gansert, Jennifer
Dubey, Sarita
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S220 - S221
[48] A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY OF GEFITINIB (G) VERSUS PLACEBO (P) IN PATIENTS (PTS) WITH ADVANCED NSCLC, NON-PROGRESSING AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY (EORTC 08021-ILCP)
Surmont, V. F.
Gaafar, R. M.
Scagliotti, G. V.
van Klaveren, R. J.
Papamichael, D.
Hasan, B.
Torri, V.
van Meerbeeck, J. P.
ANNALS OF ONCOLOGY, 2010, 21 : 124 - 124
[49] Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
Cortes, Javier
Cescon, David W.
Rugo, Hope S.
Nowecki, Zbigniew
Im, Seock-Ah
Yusof, Mastura Md
Gallardo, Carlos
Lipatov, Oleg
Barrios, Carlos Henrique
Perez-Garcia, Jose
Iwata, Hiroji
Masuda, Norikazu
Otero, Marco Torregroza
Gokmen, Erhan
Loi, Sherene
Guo, Zifang
Zhou, Xuan
Karantza, Vassiliki
Pan, Wilbur
Schmid, Peter
CANCER RESEARCH, 2022, 82 (04)
[50] PEMBROLIZUMAB (PEMBRO) VS PLACEBO AS POST NEPHRECTOMY ADJUVANT THERAPY FOR PATIENTS (PTS) WITH RENAL CELL CARCINOMA (RCC): RANDOMIZED, DOUBLE-BLIND, PHASE 3 KEYNOTE-564 STUDY
Choueiri, Toni
Tomczak, Piotr
Park, Se Hoon
Venugopal, Balaji
Ferguson, Thomas
Chang, Yen-Hwa
Hajek, Jaroslav
Symeonides, Stefan N.
Lee, Jae Lyun
Sarwar, Naveed
Thiery-Vuillemin, Antoine
Gross-Goupil, Marine
Mahave, Mauricio
Haas, Naomi
Sawrycki, Piotr
Zhang, Pingye
Imai, Kentaro
Willemann-Rogerio, Jaqueline
Quinn, David
Powles, Thomas
JOURNAL OF UROLOGY, 2021, 206 : E1181 - E1181

← 1 2 3 4 5 →